Innovative treatments reach only half of Belgian patients, warns pharma leader

EURACTIV - Belgium continues to rank among Europe's most active centres for clinical research, yet policymakers in Brussels warn that the country's competitiveness is increasingly strained by a widening gap between cutting‑edge trial activity and the pace at which patients gain access to new therapies. Read more

Katrien De Vos, managing director of MSD Belgium and Luxembourg [Photo Credit: MSD Belgium ]